Glenmark pharmaceuticals limited, Company

Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today launched SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer in India.The drug is launched at a MRP that is approx. 96 per cent lower than the MRP compared to the innovator brand, priced at Rs 7000 (50 mg), Rs 3600 (25 mg) and Rs 1840 (12.5 mg) per month. Sunitinib is also approved by the US Food and Drug Administration (US FDA).Kidney cancer (renal cell carcinoma) is a disease of uncontrolled cell growth in the lining of small tubes in the kidney. In the past decade, advances in research and drug development have begun to shift the paradigm of this disease.Sunitinib is an oral multi-kinase inhibitor (MKI), works by blocking several enzymes that promote cell growth. It is useful for the treatment of certain patients with gastrointestinal stromal tumors and advanced renal cell carcinoma. It is also approved for patients with certain type of Pancreatic Neuroendocrine Tumours.According to a Globocan 2020 report, there are close to 40,000 patients with renal cancer in India. For over a decade, Sunitinib has been well recognized as one of the "gold-standard" of care in cases of fast-spreading (metastatic) renal cancer. Research shows that Sunitinib alone has helped reduce the risk of progression of renal cancer by 58 per cent."Oncology is an important focus area for Glenmark. We recognize that advanced kidney cancer is a complex disease and patients in India are faced with limited treatment options. Glenmark is committed to bringing targeted and effective medicines at an affordable cost to physicians and their patients," said Alok Malik, Group Vice President & Business Head, India Formulations, commenting on the launch.This story is provided by PRNewswire. will not be responsible in any way for the content of this article. (/PRNewswire)( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Glenmark Pharmaceuticals LimitedFOLLOW

Glenmark pharmaceuticals limited, Latest News

Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company, is concluding the final, national phase of its marketing approval application process to enable launch of its innovative nasal spray in 17 countries in the Eu ...

Moderna announced on Tuesday (local time) that their coronavirus vaccine was 90 per cent effective six months after a person receives their second dose. ...

TVS Motor Company registered sales of 322,683 units in March 2021 as against 144,739 units in March 2020. ...

Glenmark Pharmaceuticals Limited (Glenmark) has received final approval from the United States Food & Drug Administration (US FDA) for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg, the generic version of Thorazine ...

Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today announced that its subsidiary Glenmark Specialty S.A. in Switzerland and an affiliate of Bausch Health Companies Inc. have entered into an exclusive licensing a ...

Mokusei Intelligence has announced that it is actively seeking partners and collaborators, especially from the education and travel sector. ...

Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today received the "India Pharma Innovation of the Year" award, as part of the India Pharma & India Medical Device Awards 2021. ...

Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today launched SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer in India. ...